image credit: Adobe Stock

FDA approves Servier’s Tibsovo as first targeted therapy for rare blood cancer

October 25, 2023


The decision, which specifically applies to adults with relapsed or refractory (R/R) MDS with an IDH1 mutation, makes Tibsovo the first targeted therapy approved for this indication.

The US regulator has also approved the use of a companion diagnostic, the Abbott RealTime IDH1 Assay, to identify eligible MDS patients.

An estimated 16,000 people in the US are diagnosed with MDS every year, and approximately 3.6% have an IDH1 mutation. The prognosis for these patients has often been associated with worse overall outcomes and an increased risk of transformation to acute myeloid leukaemia (AML).

Read More on PMLiVE